Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Synthetic statins: More data on newer lipid-lowering agents
Autore:
Wierzbicki, AS;
Indirizzi:
St Thomas Hosp, Dept Chem Pathol, London SE1 7EH, England St Thomas Hosp London England SE1 7EH em Pathol, London SE1 7EH, England
Titolo Testata:
CURRENT MEDICAL RESEARCH AND OPINION
fascicolo: 1, volume: 17, anno: 2001,
pagine: 74 - 77
SICI:
0300-7995(2001)17:1<74:SSMDON>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; COA REDUCTASE INHIBITORS; C-REACTIVE PROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; ATORVASTATIN; FLUVASTATIN; SIMVASTATIN; HYPERTRIGLYCERIDEMIA; ANGIOPLASTY;
Keywords:
HMG-CoA reductase inhibitors (statins); HDL-cholesterol; HDL-cholesterol; C-reactive protein; randomised controlled trials;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
34
Recensione:
Indirizzi per estratti:
Indirizzo: Wierzbicki, AS St Thomas Hosp, Dept Chem Pathol, Lambeth Palace Rd, LondonSE1 7EH, England St Thomas Hosp Lambeth Palace Rd London England SE1 7EH nd
Citazione:
A.S. Wierzbicki, "Synthetic statins: More data on newer lipid-lowering agents", CURR MED R, 17(1), 2001, pp. 74-77

Abstract

Extensive trial evidence supports the use of hydroxy-methyl-glutaryl-CoA reductase inhibitors (HMG-CoA-RI; statins) in atherosclerotic disease. Statins can be divided into two broad groups: the 'natural' statins derived froma fungal metabolites, and synthetic compounds. Whether all statins have similar anti-atherosclerotic properties, or whether these actions are specific to the 'natural' statins, is controversial. This commentary reviews the differences between natural and synthetic statins with regard to lipid-lowering and non-lipid-lowering effects, including their action on the acute phase reactant G-reactive protein. Among the newer synthetic statins, fluvastatin has some positive end-point evidence while cerivastatin shares many biochemical properties with the 'natural' statins. Extensive clinical trial programmes are underway with both atorvastatin and cerivastatin. These trialswill give a definitive answer to the question of whether synthetic statinsare as equally efficacious as 'natural' statins in preventing atherosclerotic events.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:56:11